You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 2, 2024

OPVEE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Opvee, and what generic alternatives are available?

Opvee is a drug marketed by Indivior and is included in one NDA. There is one patent protecting this drug.

This drug has eleven patent family members in eight countries.

The generic ingredient in OPVEE is nalmefene hydrochloride. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the nalmefene hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Opvee

A generic version of OPVEE was approved as nalmefene hydrochloride by PURDUE PHARMA LP on February 8th, 2022.

  Try a Trial

Summary for OPVEE
International Patents:11
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Formulation / Manufacturing:see details
Drug Prices: Drug price information for OPVEE
What excipients (inactive ingredients) are in OPVEE?OPVEE excipients list
DailyMed Link:OPVEE at DailyMed
Drug patent expirations by year for OPVEE
Drug Prices for OPVEE

See drug prices for OPVEE

Pharmacology for OPVEE
Drug ClassOpioid Antagonist
Mechanism of ActionOpioid Antagonists

US Patents and Regulatory Information for OPVEE

OPVEE is protected by one US patents and one FDA Regulatory Exclusivity.

Patents protecting OPVEE


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATING OPIOID OVERDOSE

FDA Regulatory Exclusivity protecting OPVEE

NEW PRODUCT
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Indivior OPVEE nalmefene hydrochloride SPRAY;NASAL 217470-001 May 22, 2023 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Indivior OPVEE nalmefene hydrochloride SPRAY;NASAL 217470-001 May 22, 2023 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for OPVEE

See the table below for patents covering OPVEE around the world.

Country Patent Number Title Estimated Expiration
Canada 3044221 COMPOSITIONS ET METHODES DE TRAITEMENT D'UNE PRISE EXCESSIVE D'OPIOIDES (COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPIOID OVERDOSE) ⤷  Try a Trial
Japan 2023140359 オピオイド過剰摂取を処置するための組成物および方法 (COMPOSITIONS AND METHODS FOR TREATMENT OF OPIOID OVERDOSE) ⤷  Try a Trial
Russian Federation 2019118465 КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ПЕРЕДОЗИРОВКИ ОПИОИДАМИ ⤷  Try a Trial
European Patent Office 3541386 COMPOSITIONS ET MÉTHODES DE TRAITEMENT D'UNE PRISE EXCESSIVE D'OPIOÏDES (COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPIOID OVERDOSE) ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2018093666 ⤷  Try a Trial
Russian Federation 2769397 КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ПЕРЕДОЗИРОВКИ ОПИОИДАМИ (COMPOSITIONS AND METHODS OF TREATING OPIOID OVERDOSE) ⤷  Try a Trial
China 110139651 用于治疗阿片样物质过量的组合物和方法 (COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPIOID OVERDOSE) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.